FOR IMMEDIATE RELEASE

Submitted New Drug Application to the SFDA on Remodulin
For Treatment of Pulmonary Arterial Hypertension

Hong Kong, Sept 12, 2011—Lee's Pharmaceutical Holdings Limited (Main Board Stock: 950: Website: www.leespharm.com) today announced that the Group has successfully submitted the application for new drug registration in China on United Therapeutics' product, **Remodulin** (treprostinil) injection, indicated for treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class II-IV symptoms by intravenous and subcutaneous administration.

Remodulin is a prostacyclin vasodilator that is indicated for treatment of PAH in patients with NYHA Class II-IV symptoms, to diminish symptoms associated with exercise. Additionally, in patients with pulmonary arterial hypertension requiring transition from Flolan® (epoprostenol sodium), Remodulin is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.

PAH is still an under-diagnosed and under-treated disease in China. Efforts have been made only in the last five years to improve the diagnosis, treatment and awareness of the problem. A patient registration campaign is under way to better understand the prevalence of this devastating disease in China. Currently available drugs in China are either delivered by inhalation or oral route. An intravenous or subcutaneous formulation such as Remodulin is needed for better management of the acute and severe conditions.

"We are extremely pleased with our partnership with United Therapeutics, and are excited about the opportunity to work on Remodulin in China," said Dr. Benjamin Li, the Chief Executive Officer of the Lee's."We are delighted that SFDA has accepted the Remodulin registration package, and look forward to moving the registration process forward."

About Remodulin (treprostinil) Injection

Indication. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). It may be administered as a continuous subcutaneous infusion or

FOR IMMEDIATE RELEASE

continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted.

In patients with PAH requiring transition from Flolan (epoprostenol sodium), Remodulin is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.

Important Safety Information

- Chronic intravenous infusions of Remodulin are delivered using an indwelling central venous catheter. This route is associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Therefore, continuous subcutaneous infusion is the preferred mode of administration.
- Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH. Remodulin is a potent pulmonary and systemic vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure. Remodulin inhibits platelet aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants. Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
- Initiation of Remodulin must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care. Therapy with Remodulin may be used for prolonged periods, and the patient's ability to administer Remodulin and care for an infusion system should be carefully considered.
- Remodulin dosage should be increased for lack of improvement in, or worsening of, symptoms and it should be decreased for excessive pharmacologic effects or for unacceptable infusion site symptoms.
- Abrupt withdrawal or sudden large reductions in dosage of Remodulin may result in worsening of PAH symptoms and should be avoided. Caution should be used in patients with hepatic or renal insufficiency.
- The most common side effects of Remodulin included those related to the method of infusion. For subcutaneous infusion, infusion site pain and infusion site reaction (redness and swelling) occurred in the majority of patients. These symptoms were often severe and could lead to treatment with narcotics or discontinuation of Remodulin. For intravenous infusion, line infections, sepsis, arm swelling, tingling sensations, bruising, and pain were most common. General side effects (>5% more than placebo) were diarrhea, jaw pain, vasodilatation, and edema.

FOR IMMEDIATE RELEASE

For more information about Remodulin, please see the Full Prescribing Information at www.Remodulin.com or call 877-UNITHER (877-864-8437).

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 17 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products.Leespharm focuses on several key therapeutic areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from 18 US, European and Japanese companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.For further information about Lee's Pharmaceutical: Website: www.leespharm.com

About United Therapeutics

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factors that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.

For further information, please contact:
Vivian Fung
Tel: (852)2314-1282
Fax: (852)2314-1708
Email: info@leespharm.com

REMODULIN is a registered trademark of United Therapeutics Corporation.